The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin

Annual Review of Pathology: Mechanisms of Disease

Volumn 8, Issue , 2013, Pages 477-512

  Weaver, Casey T ^a   Elson, Charles O ^b   Fouser, Lynette A ^c   Kolls, Jay K ^d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c NONE

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Asthma; Atopic dermatitis; Autoimmunity; COPD; Crohn's disease; Inflammatory bowel disease; Psoriasis; Th22 cells; Ulcerative colitis

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 26; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MUCIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; SECRETORY IMMUNOGLOBULIN; STAT3 PROTEIN; STAT5 PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR 5; UNINDEXED DRUG; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ASTHMA; ATOPIC DERMATITIS; BACTERIAL GENE; BASEMENT MEMBRANE; BRONCHIOLITIS OBLITERANS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CITROBACTER RODENTIUM; COMMENSAL; CROHN DISEASE; CYTOKINE RESPONSE; DEFENSE MECHANISM; DERMATITIS; DISEASE COURSE; ENTERITIS; GAS EXCHANGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; GRANULOMATOUS INFLAMMATION; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOREGULATION; KERATINOCYTE; LUNG CANCER; MEMORY T LYMPHOCYTE; NONHUMAN; NUTRIENT UPTAKE; PHAGOCYTE; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS; ANIMAL; COLITIS; IMMUNOLOGY;

ANIMALS; COLITIS; DERMATITIS; HUMANS; IMMUNOLOGIC FACTORS; PNEUMONIA; TH17 CELLS;

MLCS; MLOWN;

EID: 84873691650     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011110-130318     Document Type: Review

References (218)

1. Coffman RL. 2006. Origins of the TH1-TH2 model: a personal perspective. Nat. Immunol. 7:539-411
2. Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-733
3. Weaver CT, Hatton RD, Mangan PR, Harrington LE. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25:821-522
4. Kastelein RA, Hunter CA, Cua DJ. 2007. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25:221-422
5. Lee YK, Mukasa R, Hatton RD, Weaver CT. 2009. Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol. 21:274-800
6. Murphy KM, Stockinger B. 2010. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 11:674-800
7. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, et al. 2011. Human TH17 cells are long-lived effector memory cells. Sci. Transl. Med. 3:104ra00
8. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, et al. 2011. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35:972-855
9. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204:1849-611
10. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, et al. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30:92-1077
11. Sonnenberg GF, Fouser LA, Artis D. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12:383-900
12. Ouyang W, Rutz S, Crellin NK, Valdez PA,Hymowitz SG. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29:71-1099
13. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 10:857-633
14. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH17, TH1 and TH2 cells. Nat. Immunol. 10:864-711
15. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. 2009. Human Th17 cells: Are they different from murine Th17 cells? Eur. J. Immunol. 39:637-400
16. Vijay-Kumar M, Aitken JD, Gewirtz AT. 2008. Toll like receptor 5: protecting the gut from enteric microbes. Semin. Immunopathol. 30:11-211
17. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, et al. 2004. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Investig. 113:1296-3066
18. Ivanov I, Atarashi K, Manel N, Brodie E, Shima T, et al. 2009. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485-988
19. Maynard CL, Weaver CT. 2009. Intestinal effector T cells in health and disease. Immunity 31:389-4000
20. Macpherson AJ, Geuking MB, McCoy KD. 2012. Homeland security: IgA immunity at the frontiers of the body. Trends Immunol. 33:160-677
21. Mucida D, Park Y, Cheroutre H. 2009. From the diet to the nucleus: Vitamin A and TGF-βjoin efforts at the mucosal interface of the intestine. Semin. Immunol. 21:14-211
22. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59-655
23. OhnmachtC,Marques R, Presley L, Sawa S, LochnerM, Eberl G. 2011. Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity. Cell. Microbiol. 13:653-599
24. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. 2010. Biology of interleukin-22. Semin. Immunopathol. 32:17-311
25. Buonocore S, Ahern PP, Uhlig HH, Ivanov, II, Littman DR, et al. 2010. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464:1371-755
26. Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, Artis D. 2011. CD4+ lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34:122-344
27. Qiu J, Heller JJ, Guo X, Chen Z-mE, Fish K, et al. 2011. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 36:92-1044
28. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, et al. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14:282-899
29. O'Connor W, Zenewicz LA, Flavell RA. 2010. The dual nature of TH17 cells: shifting the focus to function. Nat. Immunol. 11:471-766
30. Lochner M, Berard M, Sawa S, Hauer S, Gaboriau-Routhiau V, et al. 2011. Restricted microbiota and absence of cognate TCR antigen leads to an unbalanced generation of Th17 cells. J. Immunol. 186:1531- 377
31. Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling HJ, et al. 2010. Lineage relationship analysis of RORγ+ innate lymphoid cells. Science 330:665-699
32. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, et al. 2009. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31:677-899
33. GeukingMB, Cahenzli J, Lawson MAE, Ng DCK, Slack E, et al. 2011. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34:794-8066
34. Wu H-J, Ivanov II, Darce J, Hattori K, Shima T, et al. 2010. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32:815-277
35. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. 2010. Microbes and Health Sackler Colloquium: ProinflammatoryTcell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 108(Suppl. 1):4615-222
36. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. 2004. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 110:55-622
37. Yang XO, Chang SH, Park H, Nurieva R, Shah B, et al. 2008. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205:1063-755
38. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. 2008. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29:947-577
39. Cox JH, Kljavin NM, Ota N, Leonard J, Roose-GirmaM, et al. 2012. Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol. 5:99-1099
40. Izcue A, Hue S, Buonocore S, Arancibia-Carcamo CV, Ahern PP, et al. 2008. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28:559-700
41. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, et al. 2006. IL-23 is essential for T cell- mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Investig. 116:1310-166
42. Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, et al. 2009. RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136:257-677
43. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, et al. 2006. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25:309-188
44. Ahern PP, SchieringC, Buonocore S,McGeachyMJ, Cua DJ, et al. 2010. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33:279-888
45. ElsonCO, Cong Y, Weaver CT, SchoebTR, McClanahan TK, et al. 2007. Monoclonal anti-interleukin- 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132:2359-700
46. ZhangZ,Zheng M, Bindas J, Schwarzenberger P,Kolls JK. 2006. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12:382-888
47. Feng T, Qin H, Wang L, Benveniste EN, Elson CO, Cong Y. 2011. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J. Immunol. 186:6313-188
48. Mikami Y, Kanai T, Sujino T, Ono Y, Hayashi A, et al. 2010. Competition between colitogenic Th1 and Th17 cells contributes to the amelioration of colitis. Eur. J. Immunol. 40:2409-222
49. StroberW, Fuss IJ. 2011. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140:1756-677
50. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, et al. 2005. Interleukin-22, a member of the IL- 10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129:969-844
51. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, et al. 2006. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290:827-388
52. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, et al. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52:65-700
53. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, et al. 2008. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57:1682-899
54. Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B. 2003. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 38:180-855
55. Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T. 2009. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 137:1736-455
56. Cosmi L, De Palma R, Santarlasci V, Maggi L, CaponeM, et al. 2008. Human interleukin-17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 205:1903-166
57. Kleinschek MA, Boniface K, Sadekova S, Grein J,Murphy EE, et al. 2009. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206:525-344
58. Budarf ML, Labbe C, David G, Rioux JD. 2009.GWAstudies: rewriting the story of IBD. Trends Genet. 25:137-466
59. Kan S-h, Mancini G, Gallagher G. 2008. Identification and characterization of multiple splice forms of the human interleukin-23 receptor αchain in mitogen-activated leukocytes. Genes Immun. 9:631-399
60. Khor B, Gardet A, Xavier RJ. 2011. Genetics and pathogenesis of inflammatory bowel disease. Nature 474:307-177
61. Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, et al. 2008. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel Dis. 14:204-122
62. Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, et al. 2008. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis. J. Clin. Investig. 118:2269-800
63. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, et al. 2004. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351:2069-799
64. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, et al. 2008. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135:1130-411
65. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, et al. 2004. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Investig. 113:1490-977
66. Heller F, Florian P, Bojarski C, Richter J, Christ M, et al. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:550-644
67. Lees CW, Barrett JC, Parkes M, Satsangi J. 2011. New IBD genetics: common pathways with other diseases. Gut 60:1739-533
68. Rabizadeh S, Rhee K-J, Wu S, Huso D, Gan CM, et al. 2007. Enterotoxigenic Bacteroides fragilis: a potential instigator of colitis. Inflamm. Bowel Dis. 13:1475-833
69. Rhee K-J, Wu S, Wu X, Huso DL, Karim B, et al. 2009. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect. Immun. 77:1708-188
70. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, et al. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-133
71. Saleh M, Trinchieri G. 2011. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat. Rev. Immunol. 11:9-200
72. Wu S, Rhee K, Albesiano E, Rabizadeh S, Wu X, et al. 2009. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15:1016-233
73. GarvyBA, EzekowitzRA, Harmsen AG. 1997. Role ofγ-interferon in the host immune and inflammatory responses to Pneumocystis carinii infection. Infect. Immun. 65:373-799
74. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. 1997. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect. Immun. 65:5052-566
75. Shellito J, Suzara VV, BlumenfeldW,Beck JM, StegerHJ, ErmakTH. 1990.Anew model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J. Clin. Investig. 85:1686-933
76. Khader SA, Gaffen SL, Kolls JK. 2009. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2:403-111
77. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, et al. 2005. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene α and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J. Immunol. 175:404-122
78. Kuestner RE,TaftDW, Haran A, BrandtCS, BrenderT, et al. 2007. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J. Immunol. 179:5462-733
79. Kao CY, Chen Y, Thai P, Wachi S, Huang F, et al. 2004. IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK andNF-κB signaling pathways. J. Immunol. 173:3482-911
80. Kreindler JL, Bertrand CA, Lee RJ, Karasic T, Aujla S, et al. 2009. Interleukin-17A induces bicarbonate secretion in normal human bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 296:257-666
81. Dorschner RA, Lopez-Garcia B, Peschel A, Kraus D, Morikawa K, et al. 2006. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J. 20:35-422
82. van den Berg A, Kuiper M, Snoek M, Timens W, Postma DS, et al. 2005. Interleukin-17 induces hyperresponsive interleukin-8 and interleukin-6 production to tumor necrosis factor α in structural lung cells. Am. J. Respir. Cell Mol. Biol. 33:97-1044
83. Vanaudenaerde BM, Wuyts WA, Dupont LJ, Van Raemdonck DE, Demedts MM, Verleden GM. 2003. Interleukin-17 stimulates release of interleukin-8 by human airway smooth muscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 22:1280-833
84. Kudo M, Melton AC, Chen C, Engler MB, Huang KE, et al. 2012. IL-17A produced by αβTcells drives airway hyper-responsiveness inmice and enhances mouse and human airway smoothmuscle contraction. Nat. Med. 18:547-544
85. Aujla SJ, Chan YR, Zheng M, FeiM, Askew DJ, et al. 2008. IL-22mediates mucosal host defense against gram-negative bacterial pneumonia. Nat. Med. 14:275-811
86. Kreda SM, Gynn MC, Fenstermacher DA, Boucher RC, Gabriel SE. 2001. Expression and localization of epithelial aquaporins in the adult human lung. Am. J. Respir. Cell Mol. Biol. 24:224-344
87. Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, et al. 2011. Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. Am. J. Respir. Cell Mol. Biol. 44:369-766
88. Ely LK, Fischer S, Garcia KC. 2009. Structural basis of receptor sharing by interleukin 17 cytokines. Nat. Immunol. 10:1245-511
89. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, et al. 2001. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194:519-277
90. Chen K, McAleer JP, Lin Y, Paterson DL, Zheng M, et al. 2011. Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity 35:997-10099
91. Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y. 2007. Resident Vδ1+ γδT cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J. Immunol. 178:4466-722
92. Li L, Huang L, Vergis AL, Ye H, Bajwa A, et al. 2010. IL-17 produced by neutrophils regulates IFN-γ- mediated neutrophil migration inmouse kidney ischemia-reperfusion injury. J. Clin. Investig. 120:331-422
93. Werner JL, Gessner MA, Lilly LM, NelsonMP, Metz AE, et al. 2011. Neutrophils produce interleukin 17A (IL-17A) in a dectin-1- and IL-23-dependentmanner during invasive fungal infection. Infect. Immun. 79:3966-777
94. Wu Q, Martin RJ, Rino JG, Breed R, Torres RM, Chu HW. 2007. IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection. Microbes Infect. 9:78-866
95. Lin Y, Ritchea S, Logar A, Slight S, MessmerM, et al. 2009. Interleukin-17 is required forThelper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31:799-8100
96. Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, et al. 2011. TH17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 9:158-655
97. Wuthrich M, Gern B, Hung CY, Ersland K, Rocco N, et al. 2011. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J. Clin. Investig. 121:554-688
98. Capobianco J, Grimberg A, Thompson BM, Antunes VB, Jasinowodolinski D, Meirelles GS. 2012. Thoracic manifestations of collagen vascular diseases. Radiographics 32:33-500
99. Panopoulos ST, Sfikakis PP. 2011. Biological treatments and connective tissue disease associated interstitial lung disease. Curr. Opin. Pulm. Med. 17:362-677
100. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, et al. 2011. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12:639-466
101. Toussirot E, Berthelot JM, Pertuiset E, Bouvard B, Gaudin P, et al. 2009. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor α-blocking agent: a case series. J. Rheumatol. 36:2421-277
102. Simonian PL, Roark CL, Wehrmann F, Lanham AK, Diaz del Valle F, et al. 2009. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J. Immunol. 182:657-655
103. Joshi AD, Fong DJ, Oak SR, Trujillo G, Flaherty KR, et al. 2009. Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am. J. Respir. Crit. CareMed. 179:705- 166
104. Simonian PL, Roark CL, Wehrmann F, Lanham AM, Born WK, et al. 2009. IL-17A-expressing T cells are essential for bacterial clearance in a murine model of hypersensitivity pneumonitis. J. Immunol. 182:6540-499
105. Brodlie M, McKean MC, Johnson GE, Anderson AE, Hilkens CM, et al. 2011. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur. Respir. J. 37:1378-855
106. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. 2011. The Th17 pathway in cystic fibrosis lung disease. Am. J. Respir. Crit. CareMed. 184:252-588
107. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, et al. 2010. Bleomycin and IL-1β- mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207:535-522
108. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. 2011. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 63:783-944
109. Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, et al. 2011. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 66:144-500
110. Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, et al. 2012. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology 51:37-466
111. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. 2009. In vitro- differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113:1365-744
112. Gowdy KM, Nugent JL, Martinu T, Potts E, Snyder LD, et al. 2012. Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis. Am. J. Respir. Cell Mol. Biol. 46:249-566
113. Yi T, Chen Y, Wang L, Du G, Huang D, et al. 2009. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 114:3101-122
114. Cao H, Lan Q, Shi Q, Zhou X, Liu G, et al. 2011. Anti-IL-23 antibody blockade of IL-23/IL-17 pathway attenuates airway obliteration in rat orthotopic tracheal transplantation. Int. Immunopharmacol. 11:569-755
115. Fan L, BensonHL, Vittal R,Mickler EA, Presson R, et al. 2011. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am. J. Transplant. 11:911-222
116. Tubby C, Harrison T, Todd I, Fairclough L. 2011. Immunological basis of reversible and fixed airways disease. Clin. Sci. 121:285-966
117. Holgate ST. 2010. A look at the pathogenesis of asthma: the need for a change in direction. Discov. Med. 9:439-477
118. Zhang JY, Wenzel SE. 2007. Tissue and BAL based biomarkers in asthma. Immunol. Allergy Clin. N. Am. 27:623-322
119. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, et al. 2006. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir. Res. 7:1355
120. Kawaguchi M, Onuchic LF, Li XD, Essayan DM, Schroeder J, et al. 2001. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J. Immunol. 167:4430-355
121. RamseyCD, Lazarus R, CamargoCA Jr, Weiss ST, Celedon JC. 2005. Polymorphisms in the interleukin 17F gene (IL17F) and asthma. Genes Immun. 6:236-411
122. Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, et al. 2006. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J. Allergy Clin. Immunol. 117:795-8011
123. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, et al. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65-688
124. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, et al. 2006. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 203:2715-255
125. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, et al. 2008. TH17 cells mediate steroidresistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181:4089-977
126. Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, et al. 2010. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat. Immunol. 11:928-355
127. PichavantM, Goya S,Meyer EH, Johnston RA, Kim HY, et al. 2008. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J. Exp. Med. 205:385-933
128. MoffattMF, Gut IG, Demenais F, Strachan DP, Bouzigon E, et al. 2010. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363:1211-211
129. Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, et al. 2011. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat. Genet. 43:887-922
130. Linden A, Hoshino H, Laan M. 2000. Airway neutrophils and interleukin-17. Eur. Respir. J. 15:973-777
131. Chen Y, Thai P, Zhao YH, Ho YS, DeSouza MM, Wu R. 2003. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J. Biol. Chem. 278:17036-433
132. Huang N, Liu L, Wang XZ, Liu D, Yin SY, Yang XD. 2008. Association of interleukin (IL)-12 and IL-27 gene polymorphisms with chronic obstructive pulmonary disease in a Chinese population. DNA Cell Biol. 27:527-311
133. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350:2645-533
134. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, et al. 2011. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365:1567-755
135. Chen K, Pociask DA, McAleer JP, Chan YR, Alcorn JF, et al. 2011. IL-17RA is required for CCL2 expression,macrophage recruitment, and emphysema in response to cigarette smoke. PloSONE6:e203333
136. Di Stefano A,CaramoriG,Gnemmi I, ContoliM, VicariC, et al. 2009.Thelper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin. Exp. Immunol. 157:316-244
137. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, et al. 2007. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat. Med. 13:567-699
138. Shan M, Yuan X, Song LZ, Roberts L, Zarinkamar N, et al. 2012. Cigarette smoke induction of osteopontin (SPP1) mediates TH17 inflammation in human and experimental emphysema. Sci. Transl. Med. 4:117ra99
139. Chen X, Wan J, Liu J, XieW, Diao X, et al. 2010. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69:348-544
140. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, et al. 2005. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small-cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 175:6177-899
141. Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, et al. 2011. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE 6:e248566
142. ZhangW, Chen Y,Wei H, Zheng C, Sun R, et al. 2008. Antiapoptotic activity of autocrine interleukin- 22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin. Cancer Res. 14:6432-399
143. Hoffjan S, Stemmler S. 2007. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br. J. Dermatol. 157:441-499
144. Marieb EN, Mallatt J, Wilhelm PB. 2005. Human Anatomy. San Francisco: Pearson/Benjamin Cummings. 818 pp.
145. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. 2009. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9:679-911
146. Clark RA, Chong B,Mirchandani N, Brinster NK, Yamanaka K, et al. 2006. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176:4431-399
147. Nestle FO, Kaplan DH, Barker J. 2009. Psoriasis. N. Engl. J. Med. 361:496-5099
148. Perera GK, Di Meglio P, Nestle FO. 2012. Psoriasis. Annu. Rev. Pathol. Mech. Dis. 7:385-4222
149. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. 2003. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br. J. Dermatol. 148:670-799
150. KellerM, Ruegg A, Werner S, Beer HD. 2008. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132:818-311
151. Song PI, Park YM, Abraham T,Harten B, Zivony A, et al. 2002. Human keratinocytes express functional CD14 and Toll-like receptor 4. J. Investig. Dermatol. 119:424-322
152. Kawai T, Akira S. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637-500
153. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, et al. 2007. Human keratinocytes express functional Toll-like receptors 3, 4, 5, and 9. J. Investig. Dermatol. 127:331-411
154. Lee Y, Kim H, Kim S, Shin MH, Kim YK, et al. 2009. Myeloid differentiation factor 88 regulates basal and UV-induced expressions of IL-6 and MMP-1 in human epidermal keratinocytes. J. Investig. Dermatol. 129:460-677
155. Sugita K, Kabashima K, Atarashi K, Shimauchi T, Kobayashi M, Tokura Y. 2007. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clin. Exp. Immunol. 147:176-833
156. Zepter K, Haffner A, Soohoo LF, De Luca D, Tang HP, et al. 1997. Induction of biologically active IL-1β-converting enzyme andmature IL-1βin human keratinocytes by inflammatory and immunologic stimuli. J. Immunol. 159:6203-88
157. ChamilosG,GangulyD, Lande R, Gregorio J, Meller S, et al. 2010. Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of TH17 responses. PLoS ONE 5:e129555
158. Dennehy KM,Willment JA, Williams DL, Brown GD. 2009. Reciprocal regulation of IL-23 and IL-12 following co-activation of dectin-1 and TLR signaling pathways. Eur. J. Immunol. 39:1379-866
159. Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. 2008. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J. Immunol. 181:5120-277
160. de Jong A, Pena-Cruz V, Cheng T-Y, Clark RA, Van Rhijn I, Moody DB. 2010. CD1a-autoreactive T cells are a normal component of the human T cell repertoire. Nat. Immunol. 11:1102-99
161. Igyarto BZ, Haley K, Ortner D, Bobr A, Gerami-Nejad M, et al. 2011. Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. Immunity 35:260-722
162. Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, et al. 1991. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J. Exp. Med. 174:1461-666
163. Homey B, Alenius H, Muller A, Soto H, Bowman EP, et al. 2002. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8:157-655
164. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, et al. 2002. IFN-γ-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int. Immunol. 14:767-733
165. Katou F, Ohtani H, Nakayama T, Ono K, Matsushima K, et al. 2001. Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am. J. Pathol. 158:1263-700
166. Kennedy-Crispin M, Billick E, Mitsui H, GulatiN, FujitaH, et al. 2012. Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity. J. Investig. Dermatol. 132:105-133
167. Stockinger B, Hirota K, Duarte J, Veldhoen M. 2011. External influences on the immune system via activation of the aryl hydrocarbon receptor. Semin. Immunol. 23:99-1055
168. Brembilla NC, Ramirez JM, Chicheportiche R, Sorg O, Saurat JH, Chizzolini C. 2011. In vivo dioxin favors interleukin-22 production by human CD4+ T cells in an aryl hydrocarbon receptor (AhR)- dependent manner. PLoS ONE 6:e187411
169. Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, et al. 2011. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Investig. Dermatol. 131:2428-377
170. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, et al. 2011. Integrative responses to IL-17 andTNF-αin human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Investig. Dermatol. 131:677-877
171. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, et al. 2009. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Investig. 119:3573-855
172. Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, et al. 2012. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J. Investig. Dermatol. 132:1416-244
173. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, et al. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271-799
174. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159:1092-1022
175. Bernard JJ, Gallo RL. 2011. Protecting the boundary: the sentinel role of host defense peptides in the skin. Cell. Mol. Life Sci. 68:2189-999
176. Ghannam S,Dejou C, Pedretti N, Giot J-P, DorghamK, et al. 2011. CCL20 and defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions. J. Immunol. 186:1411-200
177. Eyerich S, Wagener J,Wenzel V, Scarponi C, Pennino D, et al. 2011. IL-22 and TNF-αrepresent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur. J. Immunol. 41:1894-9011
178. Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, et al. 2009. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur. J. Immunol. 39:3570-811
179. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Investig. Dermatol. 113:752-599
180. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, et al. 1994. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Investig. Dermatol. 102:145-499
181. Kauffman CL, AriaN, Toichi E,McCormick TS, Cooper KD, et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis. J. Investig. Dermatol. 123:1037-444
182. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, et al. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356:580-922
183. Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, et al. 2011. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat. Biotechnol. 29:615-244
184. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, et al. 2012. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br. J. Dermatol. 166:861-722
185. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, et al. 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80:273-900
186. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, et al. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 41:199-2044
187. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, et al. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2:52-722
188. Guttman-Yassky E, Nograles KE, Krueger JG. 2011. Contrasting pathogenesis of atopic dermatitis and psoriasis. Part II: Immune cell subsets and therapeutic concepts. J. Allergy Clin. Immunol. 127:1420-322
189. Helms C, Saccone NL, Cao L, Daw JA, Cao K, et al. 2005. Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum. Genet. 118:466-766
190. Lande R, Gilliet M. 2010. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann. N.Y. Acad. Sci. 1183:89-1033
191. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174:3695-7022
192. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, et al. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178:2229-400
193. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, et al. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis: erratum. J. Immunol. 178:74877
194. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, et al. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Investig. Dermatol. 128:1207-111
195. Alwawi EA, Krulig E, Gordon KB. 2009. Long-term efficacy of biologics in the treatment of psoriasis: What do we really know? Dermatol. Therapy 22:431-400
196. Zaba LC, Suarez-FarinasM, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, et al. 2009. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124:1022-100
197. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez Farinas M, et al. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204:3183-944
198. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG. 2011. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J. Investig. Dermatol. 131:391-4000
199. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, et al. 2010. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362:118-288
200. Guttman-Yassky E, Nograles KE, Krueger JG. 2011. Contrasting pathogenesis of atopic dermatitis and psoriasis. Part I: Clinical and pathologic concepts. J. Allergy Clin. Immunol. 127:1110-188
201. Oyoshi MK, He R, Kumar L, Yoon J, Geha RS. 2009. Cellular and molecular mechanisms in atopic dermatitis. Adv. Immunol. 102:135-2266
202. Sandilands A, Sutherland C, Irvine AD, McLean WHI. 2009. Filaggrin in the frontline: role in skin barrier function and disease. J. Cell Sci. 122:1285-944
203. Paternoster L, Standl M, Chen C-M, Ramasamy A, Bonelykke K, et al. 2012. Meta-analysis of genomewide association studies identifies three new risk loci for atopic dermatitis. Nat. Genet. 44:187-922
204. Sims JE, Smith DE. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10:89-1022
205. Lefrancais E, Roga S, GautierV,Gonzalez-de-Peredo A,Monsarrat B, et al. 2012. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. USA 109:1673-388
206. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-900
207. Savinko T, Matikainen S, Saarialho-Kere U, Lehto M, Wang G, et al. 2012. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering ractors. J. Investig. Dermatol. 132:1392-4000
208. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, et al. 2008. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J. Immunol. 181:7420-277
209. Nakatsuji T,Gallo RL. 2012. Antimicrobial peptides: old molecules with new ideas. J. Investig. Dermatol. 132:887-955
210. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, et al. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347:1151-600
211. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, et al. 2009. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J. Allergy Clin. Immunol. 123:1244-522
212. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, et al. 2004. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J. Clin. Investig. 113:701-88
213. Mizumoto N, Takashima A. 2004. CD1a and langerin: acting as more than Langerhans cell markers. J. Clin. Investig. 113:658-600
214. Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. 2009. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc. Natl. Acad. Sci. USA 106:21795-8000
215. Suarez-Farinas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, et al. 2011. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 127:954-644
216. Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, et al. 2011. Mutual antagonism of T cells causing psoriasis and atopic eczema. N. Engl. J. Med. 365:231-388
217. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. 2012. Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity. Nature 483:227-311
218. Alcorn JF, Crowe CR, Kolls JK. 2010. TH17 cells in asthma and COPD. Annu. Rev. Physiol. 72:495-5166